Sagimet Biosciences (SGMT) Cash & Equivalents (2023 - 2024)
Sagimet Biosciences (SGMT) has 2 years of Cash & Equivalents data on record, last reported at $77.0 million in Q3 2024.
- For Q3 2024, Cash & Equivalents fell 24.35% year-over-year to $77.0 million; the TTM value through Sep 2024 reached $77.0 million, down 24.35%, while the annual FY2023 figure was $75.1 million, N/A changed from the prior year.
- Cash & Equivalents reached $77.0 million in Q3 2024 per SGMT's latest filing, down from $96.0 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $176.8 million in Q1 2024 and bottomed at $18.5 million in Q2 2023.